TrialNet: Diabetes Type 1 Prevention

描述(申请人提供)：在过去的几年里，通过TrialNet、免疫耐受网络和其他机构的努力，已经确定了多种可以改变1型糖尿病病程的治疗方法。虽然这些免疫疗法可以阻止那些血糖升高的人的疾病进展，但在大多数研究对象中，这种效果被证明是短暂的。1型糖尿病试验网络及其临床中心和附属机构的持续努力 是继续开发更好的疗法来预防和逆转人类受试者的1型糖尿病。从DPT-1开始到TrialNet，Barbara Davis中心及其附属网络一直是这些努力的核心贡献者，我们希望随着我们临床中心的更新，能够继续推动这些目标，并培养下一代能够在迄今完成的工作基础上再接再厉的内科科学家。我们的目标不仅是进行出色的临床研究，回答正在研究的主要研究问题：最常见的是糖耐量受损、显性糖尿病或C肽减少的代谢发展，而且开发免疫生物标记物，帮助我们更好地了解疾病进展的机制，并识别应答群体的辅助标记物，使我们能够更好地定制我们的治疗方法，以成功预防T1D。

DESCRIPTION (provided by applicant): Multiple treatments that can change the course of type 1 diabetes have been identified over the last several years through the efforts of TrialNet, the Immune Tolerance Network and others. Although these immune therapies can stop disease progression in those with elevated blood sugars, the effect has proven to be transient in most study subjects. The ongoing effort of Type 1 Diabetes TrialNet, its Clinical Centers and affiliates is to continue to develop better therapies to prevent and reverse type 1 diabetes in human subjects. The Barbara Davis Center and its affiliate network has been a central contributor to these efforts from the beginning of DPT-1 through TrialNet and we hope with renewal of our Clinical Center to be able to continue to push towards these aims as well as develop the next generation of physician-scientists who can build on the work accomplished so far. Our aim is not only to conduct excellent clinical research which can answer the main study questions being examined: most often metabolic - development of impaired glucose tolerance, overt diabetes or reduced C-peptide, but also to develop immune biomarkers which can help us better understand the pathogenesis of disease progression and identify secondary markers of responder groups that allow us to better tailor our therapies to achieve successful prevention of T1D.